Etienne Jornod commented: “We took the time needed to evaluate several candidates. One alternative would have been to choose an outstanding pharma specialist, but one who was not familiar with the “close access to patients” model, or to bring on a manager who knows Vifor Pharma very well and comes precisely from this area. We opted for these variant because of the excellent knowledge Stefan Schulze brings to further developing the business model of Vifor Pharma.” With this decision, the management of the company is entrusted to two individuals who are highly familiar with the unique business model of Vifor Pharma – combining expertise in pharma with innovative positioning of products and services based on its in-depth understanding of patient needs in nephrology through the partnership with Fresenius Medical Care – and who have contributed to its development. In addition, Vifor Pharma can count on an Expanded Executive Committee (EEC) which, following recent reinforcements, is primarily composed of leaders with extensive pharma experience and who have overseen or contributed to important product launches in Europe, the USA and other countries. http://liamandersonproject.denaliinstitute.org/2016/08/07/helpful-answers-for-speedy-tactics-for-doctorFurthermore, Christoph Springer will become Head of Global Business Development of Vifor Pharma in addition to his position as Vice-CEO of VFMCRP. With this experienced management team, Vifor Pharma is well placed to maximise its growth and development opportunities and meet the major challenges ahead. These include integrating the recently acquired US company Relypsa and launching Veltassa, continuing the strong growth of Vifor Pharma in general (sales +35% in the first half of 2016) and of Ferinject/Injectafer in particular (sales +46% in the first half of 2016) and preparing for a future as an independent listed company, which is expected to take place in 2017, assuming that no major market changes or special risks occur during the period. Read More Stefan Schulze (51) has been CEO of VFMCRP, the common company of Galenica and Fresenius Medical Care, since 2014. Prior to that he held various senior positions as Executive Vice President Sales & Marketing and President & General Manager of Fresenius HemoCare’s Adsorber Technology Business Unit, Germany; President of Fresenius HemoCare, USA; and Senior Vice President Business Development at Fresenius Medical Care North America, Germany and USA. Over recent years as CEO of VFMCRP, Stefan Schulze has demonstrated his talents as an entrepreneur and leader. preparing for interviewsHe has implemented the strategy of the Board of Directors in a focused and targeted manner and entered into new licensing and distribution agreements for promising products including Mircera, Retacrit TM and Rayaldee, with global partners.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/appointments-galenica-group-management-vifor-060654551.html
The first issue to bear in mind is that Russian, Ukrainian ladies are unique in that they seem to mature at a remarkably young age. You can improve your chances of getting the loan modification deal. Binaries can be complex to understand and its worth investing some time to fully comprehend them. Obtain a detailed price breakdown of the program to include any weekly, monthly or annual membership or program fees. Master of Music Degree in Piano Performance. Rising children is considered to be mainly female prerogative. In this video, my dogs Olive and Bronco are acting out a little story. It is not difficult to find out where celebrities are going to be. Chronological resumes list out the experience and qualification in a chronological order. This category is widely used by the advertisers as it creates a successful combination of silly but beautiful woman.
You may also be interested to read
- hop over to this website
- interview skills weakness
- interview skills strengths and weaknesses question